• Cheryl Austein Casnoff
  • Roland Gamache
  • La Quasha Gaddis
Part of the Health Informatics book series (HI)


The purpose of this chapter is to discuss the potential of using health information technologies to help address the current opioid epidemic. The use of technology has become a practical way to disseminate health information. New platforms for integrating medical care and digital technology have been developed to further enhance patient-provider communication. Such technological tools include electronic medical records (EMR), telemedicine, and patient portals. With an ever-growing and rapidly changing healthcare delivery system, it is necessary for providers to adapt to these changes that will help provide an efficient level of care to patients. While individual studies have been published regarding specific technologies, this chapter provides a broad overview of how a range of health IT can serve as tools to prevent and treat opioid abuse. The chapter also addresses some interoperability and privacy challenges that must be addressed to assure the most effective use of health IT to help address the epidemic.

There is general consensus that the overuse of prescription opioids has contributed to the increase in opioid overdose and addiction. To respond to this crisis, it is important to better understand the profile of the abuser of these substances in the community. There are several tools and techniques that have been employed by communities to respond to the opioid crisis.


Opioid Health IT Substance abuse Drug use Overdose Telehealth PDMP Medication assisted treatment Syndromic surveillance system 


  1. AHRQ. Increasing access to opioid abuse treatment. n.d. Accessed 14 May 2018.
  2. Becker’s Healthcare. The pivotal role of telehealth in value-based care success. 2016. Accessed 14 May 2018.
  3. Brady JE, Wunsch H, DiMaggio C, Lang BH, Giglio J, Li G. Prescription drug monitoring and dispensing of prescription opioids. Public Health Rep. 2014;129(2):139–47.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Brandeis University. PDMP prescriber use mandates: characteristics, current status, and outcomes in selected states. 2016. Accessed 14 May 2018.
  5. Brookings. A nation in overdose peril: pinpointing the most impacted communities and local gaps in care. 2017. Accessed 14 May 2018.
  6. Center for Connected Health Policy. Online prescribing. 2018. Accessed 14 May 2018.
  7. Centers for Disease Control and Prevention. Understanding the epidemic. 2017a. Accessed 14 May 2018.
  8. Centers for Disease Control and Prevention. What states need to know about PDMPs. 2017b. Accessed 14 May 2018.
  9. Centers for Disease Control and Prevention. Opioid overdose. 2017c. Accessed 14 May 2018.
  10. Commission on Combating Drug Addiction and the Opioid Crisis Interim Report. 2016. Accessed 14 May 2018.
  11. Conway M, O’Connor D. Social media, big data, and mental health: current advances and ethical implications. Curr Opin Psychol. 2016;9:77–82.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Cummings JR, Wen H, Ko M, Druss BG. Race/ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States. JAMA Psychiat. 2014;71(2):190–6.CrossRefGoogle Scholar
  13. Department of Health and Human Services. 42 CFR Part 2. 2016. Accessed 14 May 2018.
  14. Doorenbos A, Eaton L, Theodore B, Sullivan M, Robinson J, Rapp S, et al. (372) TelePain: improving primary care pain management. J Pain. 2017;18(4):S67–S8.CrossRefGoogle Scholar
  15. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014;30(7):557–64.PubMedPubMedCentralGoogle Scholar
  16. Fabrega H Jr, Ulrich R, Cornelius J. Sociocultural and clinical characteristics of patients with comorbid depressions: a comparison of substance abuse and non-substance abuse diagnoses. Compr Psychiatry. 1993;34(5):312–21.CrossRefPubMedGoogle Scholar
  17. Federal Register. Confidentiality of substance use disorder patient records. RIN:0930-AA21. Sect. CFR:42 CFR Part 2. 2017. Accessed 14 May 2018.
  18. Goldman-Mellor S, Jia Y, Kwan K, Rutledge J. Syndromic surveillance of mental and substance use disorders: a validation study using emergency department chief complaints. Psychiatr Serv. 2017;69(1):55–60.CrossRefPubMedGoogle Scholar
  19. Health Affairs. Pharmacy benefit management of opioid prescribing: the role of employers and insurers. 2017. Accessed 14 May 2018.
  20. HealthIT. Opioids. 2018. Accessed 14 May 2018.
  21. Health communication and health information technology. 2016. Accessed 14 May 2018.
  22. Heartland. Opioid epidemic gets a helping hand from telehealth. 2017. Accessed 14 May 2018.
  23. Hopson L, Wodarski J, Tang N. The effectiveness of electronic approaches to substance abuse prevention for adolescents. J Evid Inf Soc Work. 2015;12(3):310–22.CrossRefPubMedGoogle Scholar
  24. Jackmon W, Blaalid B, Chester-Adam H. Child and adolescent drug abuse prevention: a rural community-based approach. S D Med. 2016:49–54.Google Scholar
  25. King VL, Stoller KB, Kidorf M, Kindbom K, Hursh S, Brady T, et al. Assessing the effectiveness of an Internet-based videoconferencing platform for delivering intensified substance abuse counseling. J Subst Abus Treat. 2009;36(3):331–8.CrossRefGoogle Scholar
  26. Lacktman NM. Telemedicine prescribing and controlled substances laws. 2017. Accessed 14 May 2018.
  27. Lefebvre RC, Bornkessel AS. Digital social networks and health. Circulation. 2013;127(17):1829–36. Scholar
  28. Macias Konstantopoulos WL, Dreifuss JA, McDermott KA, Parry BA, Howell ML, Mandler RN, et al. Identifying patients with problematic drug use in the emergency department: results of a multisite study. Ann Emerg Med. 2014;64(5):516–25.CrossRefPubMedGoogle Scholar
  29. Mazumdar S, McRae IS, Islam MM. How can geographical information systems and spatial analysis inform a response to prescription opioid misuse? A discussion in the context of existing literature. Curr Drug Abuse Rev. 2015;8(2):104–10.CrossRefPubMedGoogle Scholar
  30. McClellan C, Ali MM, Mutter R, Kroutil L, Landwehr J. Using social media to monitor mental health discussions - evidence from twitter. J Am Med Inform Assoc. 2017;24(3):496–502.PubMedGoogle Scholar
  31. Medicaid. Telemedicine. 2018. Accessed 14 May 2018.
  32. National Association of State Alcohol and Drug Abuse Directors. Telehealth in state substance use disorder (SUD) services. 2009. content/uploads/2015/03/Telehealth-in-State-Substance-Use-Disorder-SUD-Services-2009.pdf. Accessed 14 May 2018.
  33. National Conference of State Legislatures. Telehealth policy trends and considerations. 2015. Accessed 14 May 2018.
  34. National Council for Prescription Drug Programs. NCPDP’s recommendations for an integrated, interoperable solution to ensure patient safe use of controlled substances. 2016. Accessed 14 May 2018.
  35. Nolan ML, Kunins HV, Lall R, Paone D. Developing syndromic surveillance to monitor and respond to adverse health events related to psychoactive substance use: methods and applications. Public Health Rep. 2017;132(1_suppl):65S–72S.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Office of the Assistant Secretary for Planning and Evaluation. Opioid abuse in the US and HHS actions to address opioid-drug related overdoses and deaths. n.d. Accessed 14 May 2018.
  37. Office of the National Coordinator for Health Information Technology. Enhancing access to prescription drug monitoring programs using health information technology. 2012. Accessed 14 May 2018.
  38. Omaki E, Castillo R, Eden K, Davis S, McDonald E, Murtaza U, et al. Using m-health tools to reduce the misuse of opioid pain relievers. Inj Prev. 2017. CrossRefPubMedGoogle Scholar
  39. Paulozzi LJ, Mack KA, Hockenberry JM. Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines - United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(26):563–8.PubMedPubMedCentralGoogle Scholar
  40. Pauly V, Frauger E, Pradel V, Rouby F, Berbis J, Natali F, et al. Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling high dosage buprenorphine abuse. Drug Alcohol Depend. 2011;113(1):29–36.CrossRefPubMedGoogle Scholar
  41. Riahi S, Fischler I, Stuckey MI, Klassen PE, Chen J. The value of electronic medical record implementation in mental health care: a case study. JMIR Med Inform. 2017;5(1):e1.CrossRefPubMedPubMedCentralGoogle Scholar
  42. SAMHSA. Opioids. 2016. Accessed 14 May 2018.
  43. SAMHSA. Behavioral health treatments and services. 2017. Accessed 14 May 2018.
  44. Sims SA, Snow LA, Porucznik CA. Surveillance of methadone-related adverse drug events using multiple public health data sources. J Biomed Inform. 2007;40(4):382–9.CrossRefPubMedGoogle Scholar
  45. Sinha S, Jensen M, Mullin S, Elkin PL. Safe opioid prescription: a SMART on FHIR approach to clinical decision support. Online J Public Health Inform. 2017;9(2):e193.CrossRefPubMedPubMedCentralGoogle Scholar
  46. The Office of the National Coordinator for Health Information Technology. 2016 Report to Congress on Health IT Progress. 2016. Accessed 14 May 2018.
  47. USDA. USDA Funds 80 Distance Learning and Telemedicine Projects 32 States. n.d. Accessed 14 May 2018.
  48. UW Medicine Health System. UW TelePain. 2017. Accessed 14 May 2018.
  49. Wells S, Rozenblum R, Park A, Dunn M, Bates DW. Personal health records for patients with chronic disease: a major opportunity. Appl Clin Inform. 2014;5(2):416–29.CrossRefPubMedPubMedCentralGoogle Scholar
  50. Ye J, Rust G, Fry-Johnson Y, Strothers H. E-mail in patient–provider communication: a systematic review. Patient Educ Couns. 2010;80(2):266–73.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Cheryl Austein Casnoff
    • 1
    • 2
    • 3
  • Roland Gamache
    • 4
  • La Quasha Gaddis
    • 5
  1. 1.MitreHealth FFRDCWindsor MillUSA
  2. 2.Biological SciencesNorthwestern UniversityEvanstonUSA
  3. 3.Department of Epidemiology and Public HealthYale Medical SchoolNew HavenUSA
  4. 4.Gamache ConsultingChalfontUSA
  5. 5.Centers for Disease Control and PreventionAtlantaUSA

Personalised recommendations